drugset / Trial / NCT00467506
Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma
Non-randomizedFactorialOpen-labelTreatment
Summary
Phase II clinical trial assessing efficacy and toxicity of pretargeted radioimmunotherapy using anti-CEAxanti-DTPA bispecific antibody and di-DTPA-131I peptide in patients with reccurrence of medullary thyroid carcinoma (abnormal calcitonin level and biomarkers doubling time lower than 5 years)
Timeline
- Start
- 2004-05
- Primary completion
- 2011-01
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-CEAxanti-DTPA bispecific antibody | Unknown | — | — |
| Subject | di-DTPA-131I | Peptide | — | — |